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Inborn errors of the urea cycle, liver malfunction and drug-induced hepatotoxicity are causes of life- 
threatening encephalopathies arising from hyperammonemia. L-Carnitine prevented entirely ammonia 
toxicity in mice when injected intraperitoneally 30 min before a lethal dose of ammonium acetate. Survival 
depends on the dose of L-carnitine injected, e.g., 0, 60, 70, 80 and 100% with 0, 1, 2, 8 and 16 mmol 
L-carnitine/kg, respectively. At the highest doses L-carnitine abolishes the convulsions that accompany 
acute ammonia intoxication. At lower doses it delayed their onset. The protective effect was associated 
with a marked decrease of blood ammonia, while in unprotected mice ammonemia was lethal in less than 
15 min. When sustained hyperammonemia was induced by urease injections, protection was also obtained. 
The mechanism of protection is under investigation, however, since L-carnitine facilitates fatty acid entry 
into mitochondria, possibly ATP or reducing equivalents are increased. 
L-Carnitine Ammonia Urea 
1. INTRODUCTION 
The toxicity of ammonia has attracted in- 
vestigators for a long time for both basic and prac- 
tical reasons. In spite of extensive knowledge of 
detoxication mechanisms for ammonia, particular- 
ly urea synthesis, the mechanism of toxicity of am- 
monia remains largely unknown. A most widely 
quoted hypothesis postulates an impairing action 
on brain energy metabolism, leading to a decrease 
in the levels of ATP [l-4]. This entails enhanced 
ATP consumption in the synthesis of glutamine 
[5], decreased ATP production because of non- 
optimal operation of the Krebs cycle [6] and inhibi- 
tion of the mechanism for introducing reducing 
equivalents into mitochondria [7]. 
The essential role of L-carnitine, as a carrier for 
the entry of fatty acids into mitochondria, where 
they undergo ,&-oxidation and yield acetyl CoA and 
reducing equivalents, has been extensively 
documented [8,9]. We reported recently the fact, 
at first glance puzzling, that ethanol protects 
against ammonia toxicity [lo, 111. Since ethanol 
would eventually be oxidized via acetyl CoA, we 
thought that administration of L-carnitine, by 
Fatty acid Acetyl CoA ATP 
facilitating mitochondrial uptake of fatty acyl 
groups, would increase the intramitochondrial 
content of acetyl CoA and the available metabolic 
energy, thus restoring the ATP levels decreased by 
ammonia. This paper shows that L-carnitine pro- 
tects mice against ammonia toxicity. 
2. MATERIALS AND METHODS 
Male Swiss albino mice weighing 25-30 g, fed a 
standard diet, were used. Acute ammonia intoxica- 
tion was produced by a single intraperitoneal injec- 
tion of ammonium acetate (12 mmol/kg body 
weight, as a 0.4 M solution). The animals 
developed clear symptoms of ammonia toxicity; 
hyperexcitability and drowsiness appeared first, 
followed by noise-induced seizures and coma. 
Clonic and tonic convulsions preceded death 
which occurred in all cases lo-15 min after the in- 
jection. In another group, the mice were injected 
intraperitoneally with increasing doses of L- 
carnitine (as 20070, w/v, solution in saline) before 
receiving the ammonium acetate. 
In a second set of experiments, mice were given 
16 mmol L-carnitine/kg body wt and then injected 
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30 min later with ammonium acetate in the follow- 
ing doses: 12 mmol/kg (L&O), 9.5 mmol/kg 
(L&J and 6 mmol/kg (non-lethal dose). 
Sustained hyperammonia was induced in 
another group of mice by intraperitoneal injections 
of jack bean urease (33 or 66 units/kg body wt). 
One hour later, some of the mice were injected 
with 16 mmol L-carnitine/kg. 
Blood and brain ammonia were assayed with 
glutamate dehydrogenase [1,2]. Blood urea was 
determined by the calorimetric method in [ 131. 
3. RESULTS AND DISCUSSION 
Table 1 shows that administration of L-carnitine 
entirely prevented eath in mice given a lethal dose 
of ammonium acetate. Symptoms of ammonia 
toxicity such as convulsions were either abolished 
or significantly delayed. 
The protective effect of L-carnitine was accom- 
panied by marked decreases in blood and brain 
ammonia (fig.1). This decrease did not result in a 
concomitant increase of urea production over and 
above that seen in the animals given ammonia on- 
ly. It should be noted that in the absence of L- 
carnitine the animals died in a few minutes at the 
high doses of ammonia used. However, with L- 
carnitine, long-term effects of high ammonia con- 
centration on urea synthesis could be tested. Thus, 
when lower doses of ammonium acetate were in- 
jected, as shown in fig. 2, it was clear that treat- 
ment with L-carnitine enhanced ureogenesis in 
Table 1 
Protective effect of L-carnitine on acute ammonia 
intoxication in mice 
L-Carnitine Mice injected Mice dead 
(mmol/kg) 
0 10 10 
1 10 4 
2 10 3 
8 10 2 
16 10 0 
32 10 0 
The animals received the indicated doses of L-carnitine 
in a single intraperitoneal injection; 30 min later they 
were given intraperitoneally 12 mm01 ammonium 
acetate/kg body wt 
‘6/ I I I I I 
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Fig. 1. Levels of blood and brain ammonia in mice 
treated with ammonium acetate, alone (closed symbols) 
or plus L-carnitine (open symbols). The animals received 
16 mmol L-carnitine/kg body wt by intraperitoneal 
injection, 30 min before receiving 12 mm01 ammonium 
acetate/kg body wt intraperitoneally. Blood samples 
were drawn from the tail vein at the indicated times, 
precipitated with 10% trichloroacetic acid and centri- 
fuged. In the supernatants ammonia (circles) was 
measured by assay with glutamate dehydrogenase [13]. 
At the time of sacrifice, brains of mice were frozen and 
homogenized in cold bidistilled water, precipitated with 
10% trichloroacetic acid and centrifuged. Brain ammo- 
nia (triangles) was determined in the supernatants as 
indicated above. Since death occurred to unprotected 
animals between 10 and 15 min, all the mice were killed 
10 min after ammonium acetate. Results are the means 
f SD of 4 animals. 
ammonia-intoxicated mice. As can be seen, blood 
urea rose in animals with or without L-carnitine, 
but this effect was more transient in animals given 
ammonia only. Also, the stimulation of urea pro- 
duction by L-carnitine seems to be somewhat 
delayed. 
A sustained hyperammonemia, produced by 
urease administration to mice [ 14,151, provides a 
model to assess the protective effect of L-carnitine 
on endogenous ammonia intoxication. Fig. 3 
shows that ammonia levels rose in both protected 
and unprotected mice. Moreover, in the animals 
given L-carnitine, as expected, blood ammonia 
was markedly more elevated, reflecting the in- 
crease in urea synthesis (as measured by in vivo in- 
corporation of [14C]bicarbonate into [14C]urea, 
unpublished) and subsequent hydrolysis by urease. 
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Fig. 2. Effects of L-carnitine on blood urea levels in mice 
given different doses of ammonium acetate. The mice 
were injected intraperitoneally with 16 mmol L- 
carnitinelkg body wt; 30 min later they were 
administered ammonium acetate by intraperitoneal 
injection in the following doses: (A) 12 mmol/kg 
(LD&; (B) 9.5 mmol/kg (LDIo); (C) 6 mmol/kg (non- 
lethal dose). Urea in the blood of mice with ammonium 
acetate alone (o), or plus L-carnitine (0) was 
determined as in [12]. Results are the means f SD of 4 
animals. 
More interestingly, in these animals blood am- 
monia reached levels which doubled those seen in 
animals dying from acute ammonia intoxication 
(fig.l), but they remained asymptomatic and sur- 
vived indefinitely. This may be very important 
because under our conditions animals can with- 
stand enormous increases of this metabolite 
without any apparent alteration and offer the 
possibility to clarify experimentally such important 
effects as long-term high ammonemia on 
astrocytes and thus on Alzheimer disease [16,17], 
or the amelioration of Reye’s syndrome and other 
encephalopathies, including the side effects of the 
use of valproate therapy [18,19]. 
Our results suggest that an appropriate supply of 
energetic compounds is necessary to avoid the 
deleterious effects of increased ammonemia. L- 
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Fig. 3. Effect of L-carnitine administration on urease- 
induced hyperammonia. The mice were given 33 (A) or 
66 (0) units of urease/kg body wt; 1 h later they re- 
ceived 16 mmol L-camitine/kg body wt. Blood samples 
were drawn from the tail vein at the indicated times. 
Ammonia was measured as indicated [13]. Results are 
the means f SD of 4 animals. 
Carnitine-induced intramitochondrial generation 
of reducing equivalents would overcome the 
ammonia-induced blocking of the malate- 
aspartate shuttle [7], leading to increased ATP 
production via oxidative phosphorylation. Also, 
increased acetyl CoA should enhance the synthesis 
of N-acetylglutamate, the physiological activator 
of carbamyl phosphate synthetase I [20], and thus 
urea synthesis with a concomitant increase in am- 
monia utilization. 
Our findings suggest hat L-carnitine could be of 
benefit in the treatment of hyperammonemias aris- 
ing from various liver diseases and in the manage- 
ment of hyperammonemic rises due to inborn er- 
rors of urea cycle. In this regard it is important to 
note that L-carnitine, which appears to be devoid 
of toxicity, is used in the treatment of car- 
diomyopathies and various muscular diseases, in 
restoring therapy in hemodialysis, and even in 
athletic training. 
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